Search Results For: The Survival
Presented here are the 5-year end-of-study results from the pivotal phase 2 trial of brentuximab vedotin in patients with relapsed/refractory (R/R) Hodgkin lymphoma (HL) after failed hematopoietic autologous stem cell transplantation. At 5 years, the overall patient population (N = 102) had an estimated overall survival (OS) rate of 41% (95% confidence interval [CI]: 31-51) and progression-free survival (PFS) rate of 22% (95% CI: 13-31). Patients who achieved a complete response (CR) to brentuximab vedotin (N = 34) had estimated OS and PFS rates of 64% (95% CI: 48-80%) and 52% (95% CI: 34-69%), respectively. The median OS and PFS were not reached in CR patients, with 13 patients (38% of all CR patients) remaining in follow-up and in remission at study closure. Of the 13 patients, 4 received consolidative hematopoietic allogeneic stem cell transplant, and 9 (9% of all enrolled patients) remain in sustained CR without receiving any further anticancer therapy after treatment with brentuximab vedotin. Of the patients who experienced treatment-emergent peripheral neuropathy, 88% experienced either resolution (73%) or improvement (14%) in symptoms. These 5-year follow-up data demonstrate that a subset of patients with R/R HL who obtained CR with single-agent brentuximab vedotin achieved long-term disease control and may potentially be cured. The trial was registered at www.clinicaltrials.gov as #NCT00848926.
Search results for: the survival
In summary, these end-of-study survival outcomes and freedom-from-progression results demonstrate that, among patients with R/R HL, a substantial fraction of patients who obtained CR with single-agent brentuximab vedotin have achieved long-term disease control and may potentially be cured.
This release contains forward-looking information about IBRANCE (palbociclib), including its potential benefits, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, uncertainties regarding the commercial success of IBRANCE; uncertainties regarding the commercial impact of the overall survival results of the PALOMA-2 trial; the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies; whether and when biologic license applications may be filed in any jurisdictions for IBRANCE for any additional indications for IBRANCE; whether and when any such applications may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product's benefits outweigh its known risks and determination of the product's efficacy and, if approved, whether IBRANCE will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of IBRANCE; uncertainties regarding the ability to obtain recommendations from advisory or technical committees and other public health authorities regarding IBRANCE and uncertainties regarding the commercial impact of any such recommendations; the impact of COVID-19 on our business, operations and financial results; and competitive developments.
SRTR supports the transplant community with analyses, in an effort to better patient results and experience. Through the evaluation of national data collected by the Organ Procurement and Transplant Network (OPTN) on transplant programs and organ procurement organizations, our program-specific reports provide wide-ranging information about transplant programs and their results. Data driven, improving patient outcomes is our number one goal. Start your search below:
After review of the literature search results, 77 studies published between 1971 and 2016 were analysed, which included data from a total of 8,184 patients. Overall mortality from AH was 26% at 28 days, 29% at 90 days and 44% at 180 days after admission. No changes in mortality over time were observed in univariable analysis at 28 days or 90 days after admission (Pearson correlation r -0.216, p = 0.098, and r 0.121 p = 0.503 respectively). A small but statistically significant increase in mortality was seen in 180-day mortality (r 0.461 p = 0.036). However, after meta-regression to adjust for other factors associated with mortality at each time point, no changes in mortality were seen. Sub-group analysis did not reveal any changes in mortality over time in different study types, or when only biopsy-proven or severe disease were considered.
Alcoholic hepatitis is an acute, life-threatening type of alcoholic liver disease. There has been ongoing research for many years in AH and many therapeutic agents have been examined for efficacy. However, our data show that mortality from AH has not improved over more than four decades. Indeed we found a small but significant increase in mortality at 180-days. This observation remained when considering only therapeutic trials where inclusion and exclusion criteria may have been more stringent. These results demonstrate the urgent need for better treatment in AH.
The early results show that, compared with the standard regimen of chemotherapy and a stem cell transplant), Yescarta improved event-free survival by 60%. Moreover, the safety results were as good or better than they are for existing third-line Yescarta treatment.
This is the first randomized controlled trial, which questioned the benefit of intensive remission induction CT prior to alloHCT for pts with r/r AML. Chemotherapy with high-dose cytarabine and mitoxantrone before alloHCT did not result in a higher overall success rate and did not confer a survival advantage. Watchful waiting followed by sequential conditioning and alloHCT resulted in comparable overall CR rates and survival. These data support sequential conditioning and alloHCT without prior remission induction CT whenever a stem cell donor is readily available. Finally, these results underline the importance of facilitating alloHCT as most effective anti-leukemic therapy in patients with r/r AML and stress the need for starting donor search at diagnosis.Disclosures: Stelljes: MSD: Consultancy, Honoraria; Jazz: Honoraria; Kite: Consultancy, Honoraria; MSD Sharp & Dohme: Consultancy; Medac: Honoraria; Novartis: Consultancy, Honoraria; Amgen: Consultancy; Pfizer: Consultancy, Honoraria, Research Funding. Middeke: Abbvie: Membership on an entity's Board of Directors or advisory committees. Bug: Pfizer: Consultancy; Jazz: Honoraria; Celgene /BMS: Consultancy, Honoraria; Gilead: Consultancy, Honoraria; Novartis: Consultancy. Wagner: Bristol Myers Squibb: Membership on an entity's Board of Directors or advisory committees, Other: Travel Grant; Kite Gilead: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Amgen: Speakers Bureau; Medac: Other: Travel Grant; Janssen: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees. Krause: Art-tempi: Honoraria; Kosmas: Honoraria; Abbvie: Other: Expenses. Jost: Jazz: Honoraria; BMS Celgene: Honoraria. Schubert: Alexion: Honoraria; Novartis: Honoraria; Roche: Other; SOBI: Honoraria; Janssen: Honoraria. Röllig: BMS: Consultancy, Honoraria; Amgen: Honoraria; AbbVie: Consultancy, Honoraria, Research Funding; Pfizer: Consultancy, Honoraria, Research Funding; Celgene: Consultancy, Honoraria; Jazz: Consultancy, Honoraria; Roche: Consultancy, Honoraria; Servier: Consultancy; Novartis: Consultancy, Honoraria, Research Funding. Alakel: Pfizer: Consultancy, Honoraria. Steffen: Jazz Pharmaceuticals: Other: Travel/Congress Participation Support; AbbVie: Other: Travel/Congress Participation Support. Schliemann: BMS: Consultancy, Other: travel grants; Jazz: Consultancy, Research Funding; Boehringer-Ingelheim: Research Funding; Astrazeneca: Consultancy; Astellas: Consultancy; Abbvie: Consultancy, Other: travel grants; Philogen S.p.A.: Consultancy, Honoraria, Research Funding; Novartis: Consultancy; Roche: Consultancy; Pfizer: Consultancy. Schetelig: BeiGene: Honoraria; BMS: Honoraria; Janssen: Honoraria; AstraZeneca: Honoraria; Abbvie: Honoraria; DKMS: Current Employment; TU Dresden, Medical Department I: Current Employment.
Few studies analyzed gender-related outcome differences of critically ill patients and found inconsistent results. This study aimed to test the independent association of gender and long-term survival of ICU patients.
Few studies analyzed gender-related differences in short- and long-term mortality of ICU patients and found inconsistent results. A large Swedish ICU study showed that male gender was associated with higher consumption of ICU resources and longer ICU stay, but with similar short-term mortality compared to women . On the contrary, male gender was associated with improved in-hospital survival in a study on sepsis and septic shock . Other ICU studies did not find relevant differences in short- and long-term survival between women and men [8, 9]. 041b061a72